73 results on '"Rademaker CM"'
Search Results
2. Pharmacokinetics and clinical efficacy of phenobarbital in asphyxiated newborns treated with hypothermia: a thermopharmacological approach.
- Author
-
van den Broek MP, Groenendaal F, Toet MC, van Straaten HL, van Hasselt JG, Huitema AD, de Vries LS, Egberts AC, Rademaker CM, van den Broek, M P H, Groenendaal, F, Toet, M C, van Straaten, H L M, van Hasselt, J G C, Huitema, A D R, de Vries, L S, Egberts, A C G, and Rademaker, C M A
- Abstract
Background and Objectives: Therapeutic hypothermia can influence the pharmacokinetics and pharmacodynamics of drugs, the discipline which is called thermopharmacology. We studied the effect of therapeutic hypothermia on the pharmacokinetics of phenobarbital in asphyxiated neonates, and the clinical efficacy and the effect of phenobarbital on the continuous amplitude-integrated electroencephalography (aEEG) in a prospective study.Patients and Methods: Data were obtained from the prospective SHIVER study, performed in two of the ten Dutch level III neonatal intensive care units. Phenobarbital data were collected between 2008 and 2010. Newborns were eligible for inclusion if they had a gestational age of at least 36 weeks and presented with perinatal asphyxia and encephalopathy. According to protocol in both hospitals an intravenous (repeated) loading dose of phenobarbital 20 mg/kg divided in 1-2 doses was administered if seizures occurred or were suspected before or during the hypothermic phase. Phenobarbital plasma concentrations were measured in plasma using a fluorescence polarization immunoassay. aEEG was monitored continuously.Results and Conclusion: A one-compartmental population pharmacokinetic/pharmacodynamic model was developed using a multi-level Markov transition model. No (clinically relevant) effect of moderate therapeutic hypothermia on phenobarbital pharmacokinetics could be identified. The observed responsiveness was 66%. While we still advise an initial loading dose of 20 mg/kg, clinicians should not be reluctant to administer an additional dose of 10-20 mg/kg. An additional dose should be given before switching to a second-line anticonvulsant drug. Based on our pharmacokinetic/pharmacodynamic model, administration of phenobarbital under hypothermia seems to reduce the transition rate from a continuous normal voltage (CNV) to discontinuous normal voltage aEEG background level in hypothermic asphyxiated newborns, which may be attributed to the additional neuroprotection of phenobarbital in infants with a CNV pattern. [ABSTRACT FROM AUTHOR]- Published
- 2012
- Full Text
- View/download PDF
3. Effects of hypothermia on pharmacokinetics and pharmacodynamics: a systematic review of preclinical and clinical studies.
- Author
-
van den Broek MP, Groenendaal F, Egberts AC, Rademaker CM, van den Broek, Marcel P H, Groenendaal, Floris, Egberts, Antoine C G, and Rademaker, Carin M A
- Abstract
Examples of clinical applications of therapeutic hypothermia in modern clinical medicine include traumatic cardiac arrest, ischaemic stroke and, more recently, acute perinatal asphyxia in neonates. The exact mechanism of (neuro)protection by hypothermia is unknown. Since most enzymatic processes exhibit temperature dependency, it can be expected that therapeutic hypothermia may cause alterations in both pharmacokinetic and pharmacodynamic parameters, which could result in an increased risk of drug toxicity or therapy failure. Generalizable knowledge about the effect of therapeutic hypothermia on pharmacokinetics and pharmacodynamics could lead to more appropriate dosing and thereby prediction of clinical effects. This article reviews the evidence on the influence of therapeutic hypothermia on individual pharmacokinetic and pharmacodynamic parameters. A literature search was conducted within the PubMed, Embase and Cochrane databases from January 1965 to September 2008, comparing pharmacokinetic and/or pharmacodynamic parameters in hypothermia and normothermia regarding preclinical (animal) and clinical (human) studies. During hypothermia, pharmacokinetic parameters alter, resulting in drug and metabolite accumulation in the plasma for the majority of drugs. Impaired clearance is the most striking effect. Based on impaired clearance, dosages should be decreased considerably, especially for drugs with a low therapeutic index. Hypothetically, high-clearance compounds are affected more than low-clearance compounds because of the additional effect of impaired hepatic blood flow. The volume of distribution also changes, which may lead to therapy failure when it increases and could lead to toxicity when it decreases. The pH-partitioning hypothesis could contribute to the changes in the volumes of distribution for weak bases and acids, depending on their acid dissociation constants and acid-base status. Pharmacodynamic parameters may also alter, depending on the hypothermic regimen, drug target location, pharmacological mechanism and metabolic pathway of inactivation. The pharmacological response changes when target sensitivity alters. Rewarming patients to normothermia can also result in toxicity or therapy failure. The integrated effect of hypothermia on pharmacokinetic and pharmacodynamic properties of individual drugs is unclear. Therefore, therapeutic drug monitoring is currently considered essential for drugs with a low therapeutic index, drugs with active metabolites, high-clearance compounds and drugs that are inactivated by enzymes at the site of effect. Because most of the studies (74%) included in this review contain preclinical data, clinical pharmacokinetic/pharmacodynamic studies are essential for the development of substantiated dose regimens to avoid toxicity and therapy failure in patients treated with hypothermia. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
4. Single-nucleotide polymorphisms in the folate pathway are associated with response to methotrexate treatment in juvenile idiopathic arthritis
- Author
-
Heijstek MW, Wulffraat NM, Eken Y, Pluijm SMF, Rademaker CMA, and de Jonge R
- Subjects
Pediatrics ,RJ1-570 ,Diseases of the musculoskeletal system ,RC925-935 - Published
- 2008
- Full Text
- View/download PDF
5. The use or generation of biomedical data and existing medicines to discover and establish new treatments for patients with rare diseases - recommendations of the IRDiRC Data Mining and Repurposing Task Force.
- Author
-
Southall NT, Natarajan M, Lau LPL, Jonker AH, Deprez B, Guilliams T, Hunter L, Rademaker CM, Hivert V, and Ardigò D
- Subjects
- Big Data, Databases, Factual, Humans, Biomedical Research, Data Mining, Drug Repositioning, Rare Diseases drug therapy
- Abstract
The number of available therapies for rare diseases remains low, as fewer than 6% of rare diseases have an approved treatment option. The International Rare Diseases Research Consortium (IRDiRC) set up the multi-stakeholder Data Mining and Repurposing (DMR) Task Force to examine the potential of applying biomedical data mining strategies to identify new opportunities to use existing pharmaceutical compounds in new ways and to accelerate the pace of drug development for rare disease patients. In reviewing past successes of data mining for drug repurposing, and planning for future biomedical research capacity, the DMR Task Force identified four strategic infrastructure investment areas to focus on in order to accelerate rare disease research productivity and drug development: (1) improving the capture and sharing of self-reported patient data, (2) better integration of existing research data, (3) increasing experimental testing capacity, and (4) sharing of rare disease research and development expertise. Additionally, the DMR Task Force also recommended a number of strategies to increase data mining and repurposing opportunities for rare diseases research as well as the development of individualized and precision medicine strategies.
- Published
- 2019
- Full Text
- View/download PDF
6. Are age-appropriate antibiotic formulations missing from the WHO list of essential medicines for children? A comparison study.
- Author
-
Ivanovska V, Leufkens HG, Rademaker CM, Zisovska E, Pijnenburg MW, van Dijk L, and Mantel-Teeuwisse AK
- Subjects
- Age Factors, Child, Drug Administration Routes, Formularies as Topic, Humans, World Health Organization, Anti-Bacterial Agents therapeutic use, Drug Compounding, Drugs, Essential
- Abstract
Objective: There is a global call for formulations, which are better suited for children of different age categories and in a variety of settings. One key public health area of interest is age-appropriate paediatric antibiotics. We aimed to identify clinically relevant paediatric formulations of antibiotics listed on pertinent formularies that were not on the WHO Essential Medicines List for Children (EMLc)., Methods: We compared four medicines lists versus the EMLc and contrasted paediatric antibiotic formulations in relation to administration routes, dosage forms and/or drug strengths. The additional formulations on comparator lists that differed from the EMLc formulations were evaluated for their added clinical values and costs., Results: The analysis was based on 26 EMLc antibiotics. Seven oral and two parenteral formulations were considered clinically relevant for paediatric use. Frequently quoted benefits of oral formulations included: filling the gap of unmet therapeutic needs in certain age/weight groups (phenoxymethylpenicillin and metronidazole oral liquids, and nitrofurantoin capsules), and simplified administration and supply advantages (amoxicillin dispersible tablets, clyndamycin capsules, cloxacillin tablets, and sulfamethoxazole+trimethoprim tablets). Lower doses of ampicillin and cefazolin powder for injection could simplify the dosing in newborns and infants, reduce the risk of medical errors, and decrease the waste of medicines, but may target only narrow age/weight groups., Conclusions: The identified additional formulations of paediatric antibiotics on comparator lists may offer clinical benefits for low-resource settings, including simplified administration and increased dosing accuracy. The complexity of both procuring and managing multiple strengths and formulations also needs to be considered., (Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.)
- Published
- 2017
- Full Text
- View/download PDF
7. Paediatric Drug Development and Formulation Design-a European Perspective.
- Author
-
Van Riet-Nales DA, Kozarewicz P, Aylward B, de Vries R, Egberts TC, Rademaker CM, and Schobben AF
- Subjects
- Europe, Excipients chemistry, Humans, Off-Label Use, Pediatrics, Tablets chemistry, Chemistry, Pharmaceutical methods, Drug Discovery methods, Pharmaceutical Preparations chemistry
- Abstract
The availability of licensed paediatric drugs is lagging behind those for adults, and there is a lack of safe formulations in suitable doses that children are able and willing to take. As a consequence, children are commonly treated with off-label or unlicensed drugs. As off-label and unlicensed drug use are associated with a greater risk for harm than on-label drug use, a range of global initiatives have been developed to realize "better" medicines for children. This review describes the challenges and achievements of the European Union to realize this goal, with a focus on paediatric drug development and formulation design. In 2007, a European Paediatric Regulation was installed enforcing companies to consider children in the early development of drugs with a new drug substance, for a new indication or with a new route of administration. The Regulation, e.g. requires companies to develop a paediatric investigation plan discussing the proposed clinical trials in children of different ages and the formulations for future marketing. Since 2013, the pharmaceutical design of any newly marketed paediatric drug should comply with the "Guideline on the Pharmaceutical Development of Medicines for Paediatric Use." Companies should, e.g. justify the route of administration, dosage form, formulation characteristics, safety of excipients, dosing frequency, container closure system, administration device, patient acceptability and user information. In this review, the guideline's key aspects are discussed with a focus on novel formulations such as mini-tablets and orodispersible films, excipients with a potential risk for harm such as azo dyes and adequate user instructions.
- Published
- 2017
- Full Text
- View/download PDF
8. Safe and effective pharmacotherapy in infants and preschool children: importance of formulation aspects.
- Author
-
van Riet-Nales DA, Schobben AF, Vromans H, Egberts TC, and Rademaker CM
- Subjects
- Administration, Oral, Age Factors, Chemistry, Pharmaceutical, Child, Preschool, Dosage Forms, Drug Therapy methods, Excipients, Humans, Infant, Solutions, Tablets, Drug Therapy standards, Pharmaceutical Preparations administration & dosage
- Abstract
Safe and effective paediatric pharmacotherapy requires careful evaluation of the type of drug substance, the necessary dose and the age-appropriateness of the formulation. Generally, the younger the child, the more the attention that is required. For decades, there has been a general lack of (authorised) formulations that children are able to and willing to take. Moreover, little was known on the impact of pharmaceutical aspects on the age-appropriateness of a paediatric medicine. As a result of legislative incentives, such knowledge is increasingly becoming available. It has become evident that rapidly dissolving tablets with a diameter of 2 mm (mini-tablets) can be used in preterm neonates and non-rapidly dissolving 2 mm mini-tablets in infants from 6 months of age. In addition, uncoated 4 mm mini-tablets can be used in infants from the age of 1 year. Also, there is some evidence that children prefer mini-tablets over a powder, suspension or syrup. Other novel types of age-appropriate oral formulations such as orodispersible films may further add to the treatment possibilities. This review provides an overview of the current knowledge on oral formulations for infants and preschool children, the advantages and disadvantages of the different types of dosage forms and the age groups by which these can likely be used., (Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/)
- Published
- 2016
- Full Text
- View/download PDF
9. Methods of administering oral formulations and child acceptability.
- Author
-
van Riet-Nales DA, Ferreira JA, Schobben AF, de Neef BJ, Egberts TC, and Rademaker CM
- Subjects
- Age Factors, Child, Preschool, Cross-Over Studies, Deglutition, Female, Humans, Infant, Male, Pharmaceutical Solutions, Powders, Suspensions, Tablets, Administration, Oral, Chemistry, Pharmaceutical, Patient Acceptance of Health Care
- Abstract
Introduction: Children may be unable or unwilling to swallow medicines. In order to avoid or accommodate any such problems, parents may decide to administer medicines other than intended. The aim of this study was to investigate how parents administered four oral placebo formulations to infants and preschool children and how the applied methods correlated with child acceptability., Methods: Parents were asked to administer a 4 mm mini-tablet, powder, suspension and syrup to their child twice on one day and to report the child characteristics and administration details in a participant diary., Results: A 151 children were included. The tablet, syrup and suspension were mostly given on their own, whereas the powder was commonly given with food or drink. Generally, the higher the child acceptability (VAS-score) of the first administration of a specific formulation, the less frequently its method of administration was changed. A change in the method of administration of the same formulation involving (a larger quantity of) food or drink generally resulted in a higher VAS-score., Conclusions: The joint administration of medicines with food or drink is an effective strategy to ensure swallowing. This study supports earlier findings that 4mm mini-tablets are a suitable dosage form from infant age., (Copyright © 2015 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
10. Correction: Neuroprotection by Argon Ventilation after Perinatal Asphyxia: A Safety Study in Newborn Piglets.
- Author
-
Alderliesten T, Favie LM, Neijzen RW, Auwärter V, Nijboer CH, Marges RE, Rademaker CM, Kempf J, van Bel F, and Groenendaal F
- Abstract
[This corrects the article DOI: 10.1371/journal.pone.0113575.].
- Published
- 2015
- Full Text
- View/download PDF
11. Maternal allopurinol administration during suspected fetal hypoxia: a novel neuroprotective intervention? A multicentre randomised placebo controlled trial.
- Author
-
Kaandorp JJ, Benders MJ, Schuit E, Rademaker CM, Oudijk MA, Porath MM, Oetomo SB, Wouters MG, van Elburg RM, Franssen MT, Bos AF, de Haan TR, Boon J, de Boer IP, Rijnders RJ, Jacobs CJ, Scheepers LH, Gavilanes DA, Bloemenkamp KW, Rijken M, van Meir CA, von Lindern JS, Huisjes AJ, Bakker SC, Mol BW, Visser GH, Van Bel F, and Derks JB
- Subjects
- Adult, Aldehydes blood, Allopurinol blood, Dinoprost analogs & derivatives, Dinoprost blood, Double-Blind Method, Female, Fetal Blood chemistry, Humans, Ketones blood, Male, Maternal-Fetal Exchange, Oxypurinol blood, Pregnancy, S100 Calcium Binding Protein beta Subunit blood, Allopurinol therapeutic use, Enzyme Inhibitors therapeutic use, Fetal Hypoxia drug therapy, Xanthine Oxidase antagonists & inhibitors
- Abstract
Objective: To determine whether maternal allopurinol treatment during suspected fetal hypoxia would reduce the release of biomarkers associated with neonatal brain damage., Design: A randomised double-blind placebo controlled multicentre trial., Patients: We studied women in labour at term with clinical indices of fetal hypoxia, prompting immediate delivery., Setting: Delivery rooms of 11 Dutch hospitals., Intervention: When immediate delivery was foreseen based on suspected fetal hypoxia, women were allocated to receive allopurinol 500 mg intravenous (ALLO) or placebo intravenous (CONT)., Main Outcome Measures: Primary endpoint was the difference in cord S100ß, a tissue-specific biomarker for brain damage., Results: 222 women were randomised to receive allopurinol (ALLO, n=111) or placebo (CONT, n=111). Cord S100ß was not significantly different between the two groups: 44.5 pg/mL (IQR 20.2-71.4) in the ALLO group versus 54.9 pg/mL (IQR 26.8-94.7) in the CONT group (difference in median -7.69 (95% CI -24.9 to 9.52)). Post hoc subgroup analysis showed a potential treatment effect of allopurinol on the proportion of infants with a cord S100ß value above the 75th percentile in girls (ALLO n=5 (12%) vs CONT n=10 (31%); risk ratio (RR) 0.37 (95% CI 0.14 to 0.99)) but not in boys (ALLO n=18 (32%) vs CONT n=15 (25%); RR 1.4 (95% CI 0.84 to 2.3)). Also, cord neuroketal levels were significantly lower in girls treated with allopurinol as compared with placebo treated girls: 18.0 pg/mL (95% CI 12.1 to 26.9) in the ALLO group versus 32.2 pg/mL (95% CI 22.7 to 45.7) in the CONT group (geometric mean difference -16.4 (95% CI -24.6 to -1.64))., Conclusions: Maternal treatment with allopurinol during fetal hypoxia did not significantly lower neuronal damage markers in cord blood. Post hoc analysis revealed a potential beneficial treatment effect in girls., Trial Registration Number: NCT00189007, Dutch Trial Register NTR1383., (Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.)
- Published
- 2015
- Full Text
- View/download PDF
12. Neuroprotection by argon ventilation after perinatal asphyxia: a safety study in newborn piglets.
- Author
-
Alderliesten T, Favie LM, Neijzen RW, Auwärter V, Nijboer CH, Marges RE, Rademaker CM, Kempf J, van Bel F, and Groenendaal F
- Subjects
- Animals, Animals, Newborn, Argon adverse effects, Asphyxia Neonatorum physiopathology, Disease Models, Animal, Heart Rate drug effects, Humans, Hypothermia physiopathology, Hypoxia-Ischemia, Brain physiopathology, Infant, Newborn, Oxygen Consumption drug effects, Swine, Ventilation, Argon administration & dosage, Asphyxia Neonatorum drug therapy, Hypothermia drug therapy, Hypoxia-Ischemia, Brain drug therapy, Neuroprotective Agents administration & dosage
- Abstract
Unlabelled: Hypothermia is ineffective in 45% of neonates with hypoxic-ischemic encephalopathy. Xenon has additive neuroprotective properties, but is expensive, and its application complicated. Argon gas is cheaper, easier to apply, and also has neuroprotective properties in experimental settings. The aim was to explore the safety of argon ventilation in newborn piglets., Methods: Eight newborn piglets (weight 1.4-3.0 kg) were used. Heart rate, blood pressure, regional cerebral saturation, and electrocortical brain activity were measured continuously. All experiments had a 30 min. baseline period, followed by three 60 min. periods of argon ventilation alternated with 30 min argon washout periods. Two animals were ventilated with increasing concentrations of argon (1h 30%, 1 h 50%, and 1 h 80%), two were subjected to 60 min. hypoxia (FiO2 0.08) before commencing 50% argon ventilation, and two animals received hypothermia following hypoxia as well as 50% argon ventilation. Two animals served as home cage controls and were terminated immediately., Results: Argon ventilation did not result in a significant change of heart rate (mean ± s.d. -3.5 ± 3.6 bpm), blood pressure (-0.60 ± 1.11 mmHg), cerebral oxygen saturation (0.3 ± 0.9%), electrocortical brain activity (-0.4 ± 0.7 µV), or blood gas values. Argon ventilation resulted in elevated argon concentrations compared to the home cage controls (34.5, 25.4, and 22.4 vs. 7.3 µl/ml)., Conclusion: Ventilation with up to 80% argon during normoxia, and 50% argon after hypoxia did not affect heart rate, blood pressure, cerebral saturation and electrocortical brain activity. Clinical safety studies of argon ventilation in humans seem justified.
- Published
- 2014
- Full Text
- View/download PDF
13. Pediatric drug formulations: a review of challenges and progress.
- Author
-
Ivanovska V, Rademaker CM, van Dijk L, and Mantel-Teeuwisse AK
- Subjects
- Child, Developing Countries, Drug Administration Routes, Drug Therapy, Female, Flavoring Agents, Humans, Male, Medication Adherence, Off-Label Use, Pharmaceutical Preparations chemistry, Pharmacokinetics, Taste, Technology, Pharmaceutical methods, Dosage Forms
- Abstract
Children differ from adults in many aspects of pharmacotherapy, including capabilities for drug administration, medicine-related toxicity, and taste preferences. It is essential that pediatric medicines are formulated to best suit a child's age, size, physiologic condition, and treatment requirements. To ensure adequate treatment of all children, different routes of administration, dosage forms, and strengths may be required. Many existing formulations are not suitable for children, which often leads to off-label and unlicensed use of adult medicines. New regulations, additional funding opportunities, and innovative collaborative research initiatives have resulted in some recent progress in the development of pediatric formulations. These advances include a paradigm shift toward oral solid formulations and a focus on novel preparations, including flexible, dispersible, and multiparticulate oral solid dosage forms. Such developments have enabled greater dose flexibility, easier administration, and better acceptance of drug formulations in children. However, new pediatric formulations address only a small part of all therapeutic needs in children; moreover, they are not always available. Five key issues need to be addressed to stimulate the further development of better medicines for children: (1) the continued prioritization of unmet formulation needs, particularly drug delivery in neonates and treatment gaps in pediatric cancers and childhood diseases in developing countries; (2) a better use of existing data to facilitate pediatric formulation development; (3) innovative technologies in adults that can be used to develop new pediatric formulations; (4) clinical feedback and practice-based evidence on the impact of novel formulations; and (5) improved access to new pediatric formulations., (Copyright © 2014 by the American Academy of Pediatrics.)
- Published
- 2014
- Full Text
- View/download PDF
14. Oral medicines for children in the European paediatric investigation plans.
- Author
-
van Riet-Nales DA, Römkens EG, Saint-Raymond A, Kozarewicz P, Schobben AF, Egberts TC, and Rademaker CM
- Subjects
- Administration, Oral, Advisory Committees, Child, Child, Preschool, Databases, Pharmaceutical, Dosage Forms, Drug Industry, Humans, Infant, Infant, Newborn, Prescription Drugs administration & dosage
- Abstract
Introduction: Pharmaceutical industry is no longer allowed to develop new medicines for use in adults only, as the 2007 Paediatric Regulation requires children to be considered also. The plans for such paediatric development called Paediatric Investigation Plans (PIPs) are subject to agreement by the European Medicines Agency (EMA) and its Paediatric Committee (PDCO). The aim of this study was to evaluate the key characteristics of oral paediatric medicines in the PIPs and the changes implemented as a result of the EMA/PDCO review., Methods: All PIPs agreed by 31 December 2011 were identified through a proprietary EMA-database. PIPs were included if they contained an agreed proposal to develop an oral medicine for children 0 to 11 years. Information on the therapeutic area (EMA classification system); target age range (as defined by industry) and pharmaceutical characteristics (active substance, dosage form(s) as listed in the PIP, strength of each dosage form, excipients in each strength of each dosage form) was extracted from the EMA website or the EMA/PDCO assessment reports., Results: A hundred and fifty PIPs were included corresponding to 16 therapeutic areas and 220 oral dosage forms in 431 strengths/compositions. Eighty-two PIPs (37%) included tablets, 44 (20%) liquids and 35 (16%) dosage forms with a specific composition/strength that were stored as a solid but swallowed as a liquid e.g. dispersible tablets. The EMA/PDCO review resulted in an increase of 13 (207 to 220) oral paediatric dosage forms and 44 (387 to 431) dosage forms with a specific composition/strength. For many PIPs, the target age range was widened and the excipient composition and usability aspects modified., Conclusion: The EMA/PDCO review realized an increase in the number of requirements for the development of oral dosage forms and a larger increase in the number of dosage forms with a specific composition/strength, both targeting younger children. Changes to their pharmaceutical design were less profound.
- Published
- 2014
- Full Text
- View/download PDF
15. Finding better ways to fill gaps in pediatric health research.
- Author
-
Viergever RF and Rademaker CM
- Subjects
- Child, Humans, Biomedical Research, Pediatrics
- Published
- 2014
- Full Text
- View/download PDF
16. Impact of computerized physician order entry (CPOE) on PICU prescribing errors.
- Author
-
Maat B, Bollen CW, van Vught AJ, Egberts TC, and Rademaker CM
- Subjects
- Child, Humans, Medication Errors statistics & numerical data, Practice Patterns, Physicians' statistics & numerical data, Prospective Studies, Intensive Care Units, Pediatric, Medical Order Entry Systems statistics & numerical data, Medication Errors prevention & control
- Published
- 2014
- Full Text
- View/download PDF
17. Rapid target allopurinol concentrations in the hypoxic fetus after maternal administration during labour.
- Author
-
Kaandorp JJ, van den Broek MP, Benders MJ, Oudijk MA, Porath MM, Bambang Oetomo S, Wouters MG, van Elburg R, Franssen MT, Bos AF, Mol BW, Visser GH, van Bel F, Rademaker CM, and Derks JB
- Subjects
- Adult, Allopurinol therapeutic use, Double-Blind Method, Female, Fetal Hypoxia prevention & control, Fetus drug effects, Fetus metabolism, Free Radical Scavengers pharmacology, Free Radical Scavengers therapeutic use, Free Radicals adverse effects, Humans, Infant, Newborn, Labor, Obstetric drug effects, Neuroprotective Agents therapeutic use, Placenta drug effects, Placenta metabolism, Pregnancy, Allopurinol pharmacology, Fetal Blood chemistry, Fetal Hypoxia drug therapy, Hypoxia-Ischemia, Brain prevention & control, Labor, Obstetric blood, Maternal-Fetal Exchange drug effects, Neuroprotective Agents pharmacology
- Abstract
Objective: Perinatal hypoxia-induced free radical formation is an important cause of hypoxic-ischaemic encephalopathy and subsequent neurodevelopmental disabilities. Allopurinol reduces the formation of free radicals, which potentially limits hypoxia-induced brain damage. We investigated placental transfer and safety of allopurinol after maternal allopurinol treatment during labour to evaluate its potential role as a neuroprotective agent in suspected fetal hypoxia., Design: We used data from a randomised, double-blind multicentre trial comparing maternal allopurinol versus placebo in case of imminent fetal hypoxia (NCT00189007)., Patients: We studied 58 women in labour at term, with suspected fetal hypoxia prompting immediate delivery, in the intervention arm of the study., Setting: Delivery rooms of 11 Dutch hospitals., Intervention: 500 mg allopurinol, intravenously to the mother, immediately prior to delivery., Main Outcome Measures: Drug disposition (maternal plasma concentrations, cord blood concentrations) and drug safety (maternal and fetal adverse events)., Results: Within 5 min after the end of maternal allopurinol infusion, target plasma concentrations of allopurinol of ≥2 mg/L were present in cord blood. Of all analysed cord blood samples, 95% (52/55) had a target allopurinol plasma concentration at the moment of delivery. No adverse events were observed in the neonates. Two mothers had a red and/or painful arm during infusion., Conclusions: A dose of 500 mg intravenous allopurinol rapidly crosses the placenta and provides target concentrations in 95% of the fetuses at the moment of delivery, which makes it potentially useful as a neuroprotective agent in perinatology with very little side effects., Trial Registration: The study is registered in the Dutch Trial Register (NTR1383) and the Clinical Trials protocol registration system (NCT00189007).
- Published
- 2014
- Full Text
- View/download PDF
18. Authors' reply to Eugenio Grillo: clinical management of seizures in newborns: diagnosis and management.
- Author
-
van Rooij LG, van den Broek MP, Rademaker CM, and de Vries LS
- Subjects
- Humans, Anticonvulsants therapeutic use, Seizures diagnosis, Seizures drug therapy
- Published
- 2013
- Full Text
- View/download PDF
19. Acceptability of different oral formulations in infants and preschool children.
- Author
-
van Riet-Nales DA, de Neef BJ, Schobben AF, Ferreira JA, Egberts TC, and Rademaker CM
- Subjects
- Administration, Oral, Child, Preschool, Cross-Over Studies, Female, Humans, Infant, Male, Netherlands, Patient Preference, Pharmaceutical Solutions administration & dosage, Powders administration & dosage, Suspensions administration & dosage, Tablets administration & dosage
- Abstract
Objective: Liquid medicines are easy to swallow. However, they may have disadvantages, such as a bad taste or refrigerated storage conditions. These disadvantages may be avoided by the use of oral solid medicines, such as powders or tablets. The aim of this study was to investigate the acceptability of and preference among four oral formulations in domiciliary infants and preschool children in The Netherlands., Methods: Parents administered four oral placebo dosage forms that were aimed at a neutral taste, at home, to their child (1-4 years of age) twice on one day following a randomised cross-over design: small (4 mm) tablet, powder, suspension and syrup. They were asked to report the child's acceptability by a score on a 10 cm visual analogue scale (VAS score) and by the result of the intake. At the end of the study, they were asked to report the preference of the child and themselves., Results: 183 children were included and 148 children were evaluated. The data revealed a period/cross-over effect. The estimate of the mean VAS score was significantly higher for the tablet than for the suspension (tablet 9.39/9.01; powder 8.84/8.20, suspension 8.26/7.90, syrup 8.35/8.19; data day 1/all days). The estimate of the mean number of intakes fully swallowed was significantly higher for the tablet than for the other formulations (all p values <0.05). Children and parents preferred the tablet and syrup over the suspension and the suspension over the powder (all p values <0.05)., Conclusions: All formulations were well accepted. The tablets were the best accepted formulation; the tablets and syrup the most preferred., Trial Registration Number: ISRCTN63138435.
- Published
- 2013
- Full Text
- View/download PDF
20. Anticonvulsant treatment of asphyxiated newborns under hypothermia with lidocaine: efficacy, safety and dosing.
- Author
-
van den Broek MP, Rademaker CM, van Straaten HL, Huitema AD, Toet MC, de Vries LS, Egberts AC, and Groenendaal F
- Subjects
- Anticonvulsants adverse effects, Dose-Response Relationship, Drug, Electroencephalography, Female, Gestational Age, Humans, Infant, Newborn, Lidocaine adverse effects, Male, Netherlands, Treatment Outcome, Anticonvulsants therapeutic use, Asphyxia Neonatorum drug therapy, Hypothermia, Induced, Lidocaine therapeutic use
- Abstract
Background: Lidocaine is an antiarrythmicum used as an anticonvulsant for neonatal seizures, also during therapeutic hypothermia following (perinatal) asphyxia. Hypothermia may affect the efficacy, safety and dosing of lidocaine in these patients., Objective: To study the efficacy and safety of lidocaine in newborns with perinatal asphyxia during moderate hypothermia, and to develop an effective and safe dosing regimen., Methods: Hypothermic newborns with perinatal asphyxia and lidocaine for seizure control were included. Efficacy was studied using continuous amplitude-integrated electroencephalography. Safety was assessed using continuous cardiac monitoring. An optimal dosing regimen was developed with simulations using data from a pharmacokinetic model. Plasma samples were collected during hypothermia on consecutive mornings., Results: A total of 22 hypothermic and 26 historical normothermic asphyxiated newborns with lidocaine were included. A response of 91% on epileptiform activity on the amplitude-integrated EEG was observed for lidocaine add-on therapy. No relationship between lidocaine or MEGX plasma concentrations and heart frequency could be identified. None of the newborns experienced cardiac arrythmias. Hypothermia reduced lidocaine clearance by 24% compared with normothermia. A novel dosing regimen was developed an initial bolus loading dose of 2 mg/kg, for patients with body weight 2.0-2.5 kg followed by consecutive continuous infusions of 6 mg/kg/h (for 3.5 h), 3 mg/kg/h (for 12 h), 1.5 mg/kg/h (for 12 h), or for patients with body weights 2.5-4.5 kg 7 mg/kg/h (for 3.5 h), 3.5 mg/kg/h (for 12 h), 1.75 mg/kg/h (for 12 h), before stopping., Conclusions: Lidocaine can be assumed to be an effective antiepileptic drug during hypothermia in asphyxiated neonates.
- Published
- 2013
- Full Text
- View/download PDF
21. Clinical pharmacy interventions in paediatric electronic prescriptions.
- Author
-
Maat B, Au YS, Bollen CW, van Vught AJ, Egberts TC, and Rademaker CM
- Subjects
- Adolescent, Case-Control Studies, Child, Child, Preschool, Cohort Studies, Female, Humans, Infant, Infant, Newborn, Male, Medication Errors prevention & control, Netherlands, Prospective Studies, Electronic Prescribing statistics & numerical data, Medication Errors statistics & numerical data, Pharmacists statistics & numerical data
- Abstract
Objective: To examine the frequency, nature and determinants of clinical pharmacy interventions in paediatric electronic prescriptions., Design: Prospective cohort with nested case-control study., Setting: Tertiary children's hospital, The Netherlands., Patients: Patients 0-18 years with at least one drug prescription admitted to hospital between 1 March 2004 and 1 January 2008, excluding patients receiving intensive care., Interventions: Electronic medication prescriptions for paediatric inpatients were verified and if necessary interventions were made by the paediatric clinical pharmacy. Prescriptions requiring intervention (cases) were compared with prescriptions not requiring interventions (controls)., Main Outcome Measures: Frequency of clinical pharmacy interventions, per 10 000 paediatric electronic prescriptions, and the determinants thereof., Results: Interventions were made for 1577 (1.1%) of 138 449 prescriptions. 81% of the interventions concerned correction of a prescription that might have had adverse clinical consequences. Interventions in prescriptions for antibacterial agents for systemic use were made most often. Most corrections concerned wrong doses (45%). 1577 cases were compared with 1983 controls. The risk of interventions was higher for children aged 1 month to 2 years than for 12-18-year-olds (OR=1.97 (95% CI 1.63 to 2.38)). The risk for 'free-text' prescriptions was five times higher than for 'standardised structured template' prescriptions. No differences were found between day, evening and night shift prescriptions. Significantly more interventions were made in the oral dosage form (OR=1.63 (95% CI 1.41 to 1.88)) and administration route (OR=1.80 (95% CI 1.55 to 2.09)) than for other reasons., Conclusions: Paediatric prescribing errors occur frequently and are not completely prevented by electronic prescribing systems. This study provides information for improvements in electronic prescribing for paediatric patients. Incorporating tailored solutions, such as minimised free-text entry, certain obligatory fields and integrated dose checking and indications, can improve the quality and efficiency of electronic prescribing in paediatrics.
- Published
- 2013
- Full Text
- View/download PDF
22. Clinical management of seizures in newborns : diagnosis and treatment.
- Author
-
van Rooij LG, van den Broek MP, Rademaker CM, and de Vries LS
- Subjects
- Anticonvulsants adverse effects, Electroencephalography, Humans, Infant, Newborn, Anticonvulsants therapeutic use, Seizures diagnosis, Seizures drug therapy
- Abstract
Neonatal seizures can be classified as tonic, clonic, myoclonic, and subtle. A clinical diagnosis is not easy as seizures are usually subtle in neonates. In the majority of newborn infants seizures are subclinical. On the other hand, not all abnormal movements identified by clinicians as clinical seizures are accompanied by electroencephalographic seizure discharges in the EEG. Precise incidence is difficult to delineate and depends on study population and criteria used for diagnosis of seizures. Controversy exists as to whether neonatal seizures themselves cause damage to the developing brain, or if the damage is primarily due to the underlying cause of the seizures. As a result of this controversy there is ongoing discussion whether all seizures (both clinical and subclinical) should be treated. In addition, when (sub)clinical seizures are treated, there is no consensus about the most appropriate treatment for neonatal seizures and how to assess the efficacy of treatment. Current therapeutic options to treat neonatal seizures (i.e. primarily first-generation antiepileptic drugs [AEDs]) are relatively ineffective. In practice, phenobarbital still remains the drug of first choice for EEG confirmed or suspected seizures. Benzodiazepines are also used in (phenobarbital) refractory cases. Several (small) studies indicate that lidocaine is an effective drug for refractory seizures as second- or third-line treatment. Although data are scarce, some AEDs with a wide acceptance in adult and pediatric neurology practice are being used to treat neonatal seizures (i.e. second-generation AEDs). These drugs are chemically different from all first-generation AEDs and they have an effect on other pathways so they provide new pharmacological targets for controlling seizures in newborns. Levetiracetam, topiramate, felbamate, bumetanide, lamotrigine and vigabatrin are examples of these second-generation AEDs. There is an urgent need for prospective, randomized, controlled trials to assess the efficacy and safety of these second-generation AEDs in neonates. The aim of this review is to provide an overview of the current knowledge of diagnosis, the effect on brain injury, and the treatment of neonatal seizures.
- Published
- 2013
- Full Text
- View/download PDF
23. The effect of a computerized prescribing and calculating system on hypo- and hyperglycemias and on prescribing time efficiency in neonatal intensive care patients.
- Author
-
Maat B, Rademaker CM, Oostveen MI, Krediet TG, Egberts TC, and Bollen CW
- Subjects
- Efficiency, Female, Glucose therapeutic use, Humans, Incidence, Infant, Newborn, Intensive Care Units, Neonatal, Male, Medication Errors prevention & control, Risk, Decision Support Systems, Clinical, Glucose administration & dosage, Hyperglycemia prevention & control, Hypoglycemia drug therapy, Intensive Care, Neonatal methods, Medical Order Entry Systems, Prescriptions
- Abstract
Background: Prescribing glucose requires complex calculations because glucose is present in parenteral and enteral nutrition and drug vehicles, making it error prone and contributing to the burden of prescribing errors., Objective: Evaluation of the impact of a computerized physician order entry (CPOE) system with clinical decision support (CDS) for glucose control in neonatal intensive care patients (NICU) focusing on hypo- and hyperglycemic episodes and prescribing time efficiency., Methods: An interrupted time-series design to examine the effect of CPOE on hypo- and hyperglycemias and a crossover simulation study to examine the influence of CPOE on prescribing time efficiency. NICU patients at risk for glucose imbalance hospitalized at the University Medical Center Utrecht during 2001-2007 were selected. The risks of hypo- and hyperglycemias were expressed as incidences per 100 patient days in consecutive 3-month intervals during 3 years before and after CPOE implementation. To assess prescribing time efficiency, time needed to calculate glucose intake with and without CPOE was measured., Results: No significant difference was found between pre- and post-CPOE mean incidences of hypo- and hyperglycemias per 100 hospital days of neonates at risk in every 3-month period (hypoglycemias, 4.0 [95% confidence interval, 3.2-4.8] pre-CPOE and 3.1 [2.7-3.5] post-CPOE, P = .88; hyperglycemias, 6.0 [4.3-7.7] pre-CPOE and 5.0 [3.7-6.3] post-CPOE, P = .75). CPOE led to a significant time reduction of 16% (1.3 [0.3-2.3] minutes) for simple and 60% (8.6 [5.1-12.1] minutes) for complex calculations., Conclusions: CPOE including a special CDS tool preserved accuracy for calculation and control of glucose intake and increased prescribing time efficiency.
- Published
- 2013
- Full Text
- View/download PDF
24. Pharmacokinetics and pharmacodynamics of medication in asphyxiated newborns during controlled hypothermia. The PharmaCool multicenter study.
- Author
-
de Haan TR, Bijleveld YA, van der Lee JH, Groenendaal F, van den Broek MP, Rademaker CM, van Straaten HL, van Weissenbruch MM, Vermeulen JR, Dijk PH, Dudink J, Rijken M, van Heijst A, Dijkman KP, Gavilanes D, van Kaam AH, Offringa M, and Mathôt RA
- Subjects
- Asphyxia Neonatorum complications, Chromatography, Liquid, Clinical Protocols, Cohort Studies, Female, Humans, Hypoxia-Ischemia, Brain etiology, Infant, Newborn, Intensive Care Units, Neonatal, Intensive Care, Neonatal, Male, Mass Spectrometry, Pharmaceutical Preparations administration & dosage, Pharmacokinetics, Pharmacology, Rewarming, Treatment Outcome, Electroencephalography drug effects, Hypothermia, Induced methods, Hypoxia-Ischemia, Brain therapy, Pharmaceutical Preparations blood, Resuscitation
- Abstract
Background: In the Netherlands, perinatal asphyxia (severe perinatal oxygen shortage) necessitating newborn resuscitation occurs in at least 200 of the 180-185.000 newly born infants per year. International randomized controlled trials have demonstrated an improved neurological outcome with therapeutic hypothermia. During hypothermia neonates receive sedative, analgesic, anti-epileptic and antibiotic drugs. So far little information is available how the pharmacokinetics (PK) and pharmacodynamics (PD) of these drugs are influenced by post resuscitation multi organ failure and the metabolic effects of the cooling treatment itself. As a result, evidence based dosing guidelines are lacking. This multicenter observational cohort study was designed to answer the question how hypothermia influences the distribution, metabolism and elimination of commonly used drugs in neonatal intensive care., Methods/design: Multicenter cohort study. All term neonates treated with hypothermia for Hypoxic Ischemic Encephalopathy (HIE) resulting from perinatal asphyxia in all ten Dutch Neonatal Intensive Care Units (NICUs) will be eligible for this study. During hypothermia and rewarming blood samples will be taken from indwelling catheters to investigate blood concentrations of several antibiotics, analgesics, sedatives and anti-epileptic drugs. For each individual drug the population PK will be characterized using Nonlinear Mixed Effects Modelling (NONMEM). It will be investigated how clearance and volume of distribution are influenced by hypothermia also taking maturation of neonate into account. Similarly, integrated PK-PD models will be developed relating the time course of drug concentration to pharmacodynamic parameters such as successful seizure treatment; pain assessment and infection clearance., Discussion: On basis of the derived population PK-PD models dosing guidelines will be developed for the application of drugs during neonatal hypothermia treatment. The results of this study will lead to an evidence based drug treatment of hypothermic neonatal patients. Results will be published in a national web based evidence based paediatric formulary, peer reviewed journals and international paediatric drug references., Trial Registration: NTR2529.
- Published
- 2012
- Full Text
- View/download PDF
25. Long-term neuroprotective effects of allopurinol after moderate perinatal asphyxia: follow-up of two randomised controlled trials.
- Author
-
Kaandorp JJ, van Bel F, Veen S, Derks JB, Groenendaal F, Rijken M, Roze E, Venema MM, Rademaker CM, Bos AF, and Benders MJ
- Subjects
- Asphyxia Neonatorum psychology, Birth Weight, Developmental Disabilities etiology, Developmental Disabilities prevention & control, Female, Follow-Up Studies, Free Radical Scavengers therapeutic use, Gestational Age, Humans, Hypoxia-Ischemia, Brain etiology, Hypoxia-Ischemia, Brain psychology, Infant, Newborn, Intelligence drug effects, Male, Neuropsychological Tests, Reperfusion Injury etiology, Reperfusion Injury psychology, Treatment Outcome, Allopurinol therapeutic use, Asphyxia Neonatorum complications, Hypoxia-Ischemia, Brain prevention & control, Neuroprotective Agents therapeutic use, Reperfusion Injury prevention & control
- Abstract
Objective: Free-radical-induced reperfusion injury has been recognised as an important cause of brain tissue damage after birth asphyxia. Allopurinol reduces the formation of free radicals, thereby potentially limiting the amount of hypoxia-reperfusion damage. In this study the long-term outcome of neonatal allopurinol treatment after birth asphyxia was examined., Design: Follow-up of 4 to 8 years of two earlier performed randomised controlled trials., Setting: Leiden University Medical Center, University Medical Center Groningen and University Medical Center Utrecht, The Netherlands., Patients: Fifty-four term infants were included when suffering from moderate-to-severe birth asphyxia in two previously performed trials., Intervention: Infants either received 40 mg/kg allopurinol (with an interval of 12 h) starting within 4 h after birth or served as controls., Main Outcome Measures: Children, who survived, were assessed with the Wechsler Preschool and Primary Scales of Intelligence test or Wechsler Intelligence Scale for Children and underwent a neurological examination. The effect of allopurinol on severe adverse outcome (defined as mortality or severe disability at the age of 4-8 years) was examined in the total group of asphyxiated infants and in a predefined subgroup of moderately asphyxiated infants (based on the amplitude integrated electroencephalogram)., Results: The mean age during follow-up (n=23) was 5 years and 5 months (SD 1 year and 2 months). There were no differences in long-term outcome between the allopurinol-treated infants and controls. However, subgroup analysis of the moderately asphyxiated group showed significantly less severe adverse outcome in the allopurinol-treated infants compared with controls (25% vs 65%; RR 0.40, 95%CI 0.17 to 0.94)., Conclusions: The reported data may suggest a (neuro)protective effect of neonatal allopurinol treatment in moderately asphyxiated infants.
- Published
- 2012
- Full Text
- View/download PDF
26. The availability and age-appropriateness of medicines authorized for children in The Netherlands.
- Author
-
van Riet-Nales DA, de Jager KE, Schobben AF, Egberts TC, and Rademaker CM
- Subjects
- Adolescent, Age Factors, Child, Child, Preschool, Drug Approval, Humans, Infant, Netherlands, Health Knowledge, Attitudes, Practice, Pharmaceutical Preparations administration & dosage, Pharmaceutical Preparations supply & distribution, Practice Patterns, Physicians' standards
- Abstract
Aim: To study the number of medicines and active chemical entities that are authorized and commercially available for children in the Netherlands and to evaluate the age-appropriateness of the available paediatric medicines., Methods: The availability of paediatric medicines and active chemical entities was studied with the help of a Dutch medicines database and the Summary of Product Characteristics. Medicines were categorized with respect to their route of administration, type of oral dosage form and therapeutic category. The age-appropriateness was assessed on three aspects: dose capability, suitability of the dosage form and inclusion of potentially harmful excipients., Results: Three thousand five hundred and forty-two paediatric medicines containing 703 different active chemical entities were identified. This equalled half of all the medicines and chemical entities available for human use. The percentage of paediatric medicines increased with age and varied for the route of administration from 22% (dermal) to 81% (inhalation) and for the therapeutic category from 11% (uro-genital, sex hormones) to 89% (anti-parasites). The appropriateness of the paediatric medicines with respect to their authorization status, dose capability and dosage form increased with age from 27-88%. Fifty-two percent of all oral paediatric liquid formulations contained a potentially harmful excipient., Conclusion: This study confirms the limited availability of paediatric medicines for a broad range of therapeutic areas and shows that paediatric medicines may not be age-appropriate, even if authorized. While confirming the need for a legislative incentive, the results also provide baseline information for an estimation of the effect of the European Paediatric Regulation in the near future., (© 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society.)
- Published
- 2011
- Full Text
- View/download PDF
27. Pharmacokinetic research in children: an analysis of registered records of clinical trials.
- Author
-
Viergever RF, Rademaker CM, and Ghersi D
- Abstract
Background: Reported off-label/unlicensed prescribing rates in children range from 11% to 80%. Research into pharmacokinetic profiles of children's medicines is essential in the creation of more knowledge on the safety and efficacy of medicines in children. This study investigated how often pharmacokinetic data are collected in clinical trials of medicines in children by analysing registered records of clinical trials., Methods: The registered records of all clinical trials in children that were recruiting on 22 May 2009 were identified on the International Clinical Trials Registry Platform using a Clinical Trials in Children search filter. The records of trials in children below 12 years of age, in which the intervention was one or more medicines, were assessed for evidence that pharmacokinetic data would be collected., Results: Of 1081 eligible trial records, 257 (24%) declared that pharmacokinetic data would be collected. Of these trials, 199 (77%) recruited in Northern America; recruitment in all other regions was below 20%. Trials recruited most often in children over 2 years of age (74%), and least often in newborn infants (32%). Most trials researched medicines in the field of cancer (29%). Trials investigated one-third of the medicines that were indicated as a priority for pharmacokinetic research by the European Medicines Agency., Conclusions: There is a need for increased knowledge of the pharmacokinetic profiles of children's medicines. The amount of currently ongoing pharmacokinetic research does not seem to address adequately the lack of knowledge in this area. This study sets a baseline for monitoring of future progress on the amount of ongoing pharmacokinetic research in children.
- Published
- 2011
- Full Text
- View/download PDF
28. High prevalence of methotrexate intolerance in juvenile idiopathic arthritis: development and validation of a methotrexate intolerance severity score.
- Author
-
Bulatović M, Heijstek MW, Verkaaik M, van Dijkhuizen EH, Armbrust W, Hoppenreijs EP, Kamphuis S, Kuis W, Egberts TC, Sinnema G, Rademaker CM, and Wulffraat NM
- Subjects
- Adolescent, Antirheumatic Agents therapeutic use, Child, Child, Preschool, Cross-Sectional Studies, Drug-Related Side Effects and Adverse Reactions etiology, Female, Humans, Male, Methotrexate therapeutic use, ROC Curve, Sensitivity and Specificity, Surveys and Questionnaires, Antirheumatic Agents adverse effects, Arthritis, Juvenile drug therapy, Drug-Related Side Effects and Adverse Reactions diagnosis, Methotrexate adverse effects
- Abstract
Objective: To design and validate a new questionnaire for identifying patients with methotrexate (MTX) intolerance, and to determine the prevalence of MTX intolerance in patients with juvenile idiopathic arthritis (JIA) using this questionnaire., Methods: The MTX Intolerance Severity Score (MISS) questionnaire was constructed, consisting of 5 domains: stomach ache, nausea, vomiting, sore mouth, and behavioral symptoms. The domains each consisted of 3 questions pertaining to the presence of a symptom upon, prior to (anticipatory), and when thinking of (associative) MTX intake. The MISS questionnaire was validated in 86 patients by determining its discriminative power between patients with and those without MTX intolerance, identified as such by a gold standard (physician's opinion). Using the MISS questionnaire, the prevalence of MTX intolerance was determined in 297 JIA patients., Results: The MISS questionnaire discriminated well between MTX-intolerant and MTX-tolerant patients. A cutoff score of 6 yielded the best sensitivity (88%) and specificity (80%). MTX intolerance was found in 150 (50.5%) of 297 patients. Of 220 patients receiving oral MTX, 98 (44.5%) experienced MTX intolerance, whereas 67.5% of 77 patients receiving parenteral MTX experienced intolerance to the drug (P = 0.001)., Conclusion: Our findings indicate that the MISS questionnaire is a highly sensitive and specific tool for the diagnosis of MTX intolerance, and that there is a high prevalence of MTX intolerance among JIA patients. The prevalence of intolerance in patients receiving parenteral MTX exceeds that in patients receiving oral MTX. The frequent occurrence of anticipatory and associative symptoms suggests that classic conditioning plays an important role in MTX intolerance., (Copyright © 2011 by the American College of Rheumatology.)
- Published
- 2011
- Full Text
- View/download PDF
29. Lidocaine (lignocaine) dosing regimen based upon a population pharmacokinetic model for preterm and term neonates with seizures.
- Author
-
van den Broek MP, Huitema AD, van Hasselt JG, Groenendaal F, Toet MC, Egberts TC, de Vries LS, and Rademaker CM
- Subjects
- Anticonvulsants adverse effects, Anticonvulsants therapeutic use, Clinical Protocols, Drug Monitoring, Female, Gestational Age, Humans, Infant, Newborn, Infant, Premature, Infant, Premature, Diseases drug therapy, Lidocaine adverse effects, Lidocaine therapeutic use, Male, Scandinavian and Nordic Countries, Anticonvulsants administration & dosage, Anticonvulsants pharmacokinetics, Arrhythmias, Cardiac chemically induced, Lidocaine administration & dosage, Lidocaine pharmacokinetics, Models, Statistical, Seizures drug therapy
- Abstract
Background and Objective: The application of lidocaine (lignocaine) as an anticonvulsant in neonates originated more than 40 years ago in Scandinavia. Lidocaine has been shown to be an effective anticonvulsant for the treatment of neonatal seizures that persist in spite of first-line anticonvulsant therapy. However, lidocaine toxicity, mainly in the form of cardiac arrhythmias, can be life threatening. Therapeutic drug monitoring can be useful to prevent toxicity. In a previous study, a dosing regimen was developed for term neonates, but it was not evaluated for preterm neonates. Extrapolation of the previously developed dosing regimen to premature neonates without accounting for differences in pharmacokinetics because of immaturity of phase I metabolism and body fat/water ratio may result in serious toxicity or therapy failure. The objective of this study was to develop an optimized dosing regimen for lidocaine in preterm as well as term neonates, using population pharmacokinetic modelling and simulation., Methods: The requirements for this dosing regimen were simplicity of implementation, equal initial doses for all weight categories and avoidance of plasma concentrations >9 mg/L. After lidocaine administration, blood samples were collected from an arterial line from a total of 46 preterm and term neonates with convulsion, within 10 days after birth. Lidocaine concentrations were measured in plasma using a fluorescence polarization immunoassay. Population pharmacokinetic modelling started with assessment of two important aspects of paediatric pharmacokinetics: relation to body size and the effects of maturation., Results: In the studied neonatal population (term and preterm neonates with gestational ages up to 10 days), gestational age and bodyweight were closely related. Therefore, the effects of allometry and maturation on lidocaine pharmacokinetics could not be described independently and were described by a combined power estimate of bodyweight on clearance and volume of distribution. Based on this pharmacokinetic model, a dosing strategy for lidocaine for neonatal seizure control was developed, which allows rapid and safe administration of lidocaine in this population. When prospective validation confirms our model, routinely performed therapeutic drug monitoring should no longer be necessary and would only be advised in cases of (suspected) clinical symptoms of over- or underdosing., Conclusion: A lidocaine dosing regimen for seizure control in preterm and term neonates has been developed using population pharmacokinetic modelling and simulation. Allometry and maturation exponents were combined into one exponent for each pharmacokinetic parameter and could not be described independently. Based on this model, this regimen allows rapid and safe administration of lidocaine in this population.
- Published
- 2011
- Full Text
- View/download PDF
30. Antibiotic weight-watching: slimming down on antibiotic use in a NICU.
- Author
-
Liem TY, Van Den Hoogen A, Rademaker CM, Egberts TC, Fleer A, and Krediet TG
- Subjects
- Humans, Infant, Newborn, Intensive Care Units, Neonatal statistics & numerical data, Intensive Care, Neonatal organization & administration, Intensive Care, Neonatal statistics & numerical data, Program Evaluation, Sepsis diagnosis, Anti-Bacterial Agents therapeutic use, Drug Utilization statistics & numerical data, Inappropriate Prescribing prevention & control, Intensive Care Units, Neonatal organization & administration, Intensive Care, Neonatal methods, Sepsis drug therapy
- Published
- 2010
- Full Text
- View/download PDF
31. Allopurinol reduces oxidative stress in the ovine fetal cardiovascular system after repeated episodes of ischemia-reperfusion.
- Author
-
Derks JB, Oudijk MA, Torrance HL, Rademaker CM, Benders MJ, Rosen KG, Cindrova-Davies T, Thakor AS, Visser GH, Burton GJ, van Bel F, and Giussani DA
- Subjects
- Allopurinol blood, Animals, Blood Pressure, Enzyme Inhibitors blood, Female, Free Radical Scavengers blood, Oxidative Stress drug effects, Oxypurinol blood, Pregnancy, Reactive Oxygen Species metabolism, Sheep, Domestic, Allopurinol pharmacology, Cardiovascular System drug effects, Cardiovascular System physiopathology, Fetus anatomy & histology, Fetus drug effects, Fetus physiology, Free Radical Scavengers pharmacology, Ischemia physiopathology, Reperfusion
- Abstract
In complicated labor, neonatal outcome may depend not only on the extent of fetal asphyxia and acidosis but also on the effects on the fetal cardiovascular system of reactive oxygen species (ROS) generated during the ischemia-reperfusion (I/R) associated with repeated compressions of the umbilical cord. This study tested the hypothesis that maternal treatment with clinical doses of the antioxidant allopurinol in the setting of fetal asphyxia would reduce oxidative stress in the fetal cardiovascular system. The hypothesis was tested in chronically instrumented fetal sheep in late gestation by investigating the effects of maternal treatment with therapeutic doses of allopurinol or vehicle on the fetal cardiovascular system during and after episodes of I/R. The latter were produced by repeated, measured compressions of the umbilical cord. The data show that maternal treatment with allopurinol helped maintain umbilical blood flow and it reduced fetal cardiac oxidative stress after I/R of the type associated with clinically relevant acidemia and repetitive fetal heart rate decelerations. The data support the hypothesis tested and suggest that maternal treatment with allopurinol may offer plausible clinical intervention in the management of perinatal asphyxia in complicated labor.
- Published
- 2010
- Full Text
- View/download PDF
32. Quantifying antibiotic use in paediatrics: a proposal for neonatal DDDs.
- Author
-
Liem TB, Heerdink ER, Egberts AC, and Rademaker CM
- Subjects
- Adolescent, Body Weight, Child, Child, Preschool, Humans, Infant, Infant, Newborn, Anti-Bacterial Agents administration & dosage, Anti-Bacterial Agents therapeutic use, Drug Dosage Calculations
- Abstract
The defined daily dose (DDD) as defined by the World Health Organization (WHO) has been the most frequently used unit of measurement to measure antibiotic use. However, measuring antibiotic use in paediatrics is a problem as the WHO DDD methodology is not applicable in children (aged >1 month) due to the large variation in body weight within this population. Based on the narrow range of body weights in the neonatal population, we therefore aimed to develop a set of neonatal DDDs for antibiotics. Eight well-respected (inter)national sources for dosage recommendations of antibiotics in children and neonates were consulted for the assumed maintenance dose of the ten most frequently used antibiotics in neonatal intensive care units in its main indication for neonates. A set of neonatal DDDs for ten commonly used antibiotics in neonates based on an assumed neonatal weight of 2 kg was proposed. Primarily in children DDDs are not applicable to quantify antibiotic use since there is large variation in body weight. In the neonatal population, however, based on its narrow range of body weights and when access to patient level data is not available, neonatal DDDs can be used as a unit of measurement.
- Published
- 2010
- Full Text
- View/download PDF
33. Variation in antibiotic use in neonatal intensive care units in the Netherlands.
- Author
-
Liem TB, Krediet TG, Fleer A, Egberts TC, and Rademaker CM
- Subjects
- Drug Utilization standards, Humans, Infant, Newborn, Intensive Care Units, Neonatal, Netherlands, Anti-Bacterial Agents therapeutic use, Bacterial Infections drug therapy, Drug Utilization statistics & numerical data
- Abstract
Objectives: To examine the variation in quantity and classes of antibiotics used in all 10 tertiary care neonatal intensive care units (NICUs) in the Netherlands during 2005., Methods: We collected data from all tertiary care NICUs in the Netherlands on clinical and demographic characteristics and the type and quantity of systemic antibiotic use [expressed as defined daily doses (DDD)/100 admissions] in 2005. Antibiotics were ranked by volume of DDDs, and those antibiotics which accounted for 90% of the total volume of use [drug utilization (DU) 90%] were noted., Results: Antibiotic consumption ranged from 130 to 360 DDD/100 admissions. In total, 9-24 different antibiotics were used, of which 3-10 were in the DU90% segment., Conclusions: By comparing antibiotic use in Dutch NICUs we found a considerable variation in the number of different antibiotics used and in the total amount of antibiotic use. Further exploration of the opportunities to reach consensus in antibiotic policy, and to increase attention to antibiotic stewardship, is recommended.
- Published
- 2010
- Full Text
- View/download PDF
34. Effects of the pharmaceutical technologic aspects of oral pediatric drugs on patient-related outcomes: a systematic literature review.
- Author
-
van Riet-Nales DA, Schobben AF, Egberts TC, and Rademaker CM
- Subjects
- Administration, Oral, Adolescent, Child, Child, Preschool, Humans, Infant, Infant, Newborn, Off-Label Use, Patient Preference, Pediatrics, Technology, Pharmaceutical, Treatment Outcome
- Abstract
Background: In view of the high rates of off-label and unlicensed prescribing of drugs in children, the US Food and Drug Administration and the European Union have implemented legislative regulations for the pharmaceutical industry to increase the number of drugs with approved pediatric labeling. However, the extent to which the effects of pharmaceutical technologic aspects of pediatric oral drugs (eg, taste, route and frequency of administration, user instructions) on patient-related outcomes (eg, efficacy, tolerability, preference, adherence) can be based on clinical evidence from the available literature is unknown., Objective: This systematic literature review aimed to identify the nature, volume, and quality of comparative studies that have assessed the effects of pharmaceutical technologic aspects of oral pediatric drugs on patient-related outcomes., Methods: The Cochrane, EMBASE, and MEDLINE databases were searched from their start through December 31, 2009. Studies were eligible for inclusion if they were published in English; included search terms for child, study design, medicine, formulation aspects, dosage form, routes of administration, patient acceptance, adherence, side effects and tolerability, and/or efficacy; reported on > or = 10 children aged 0 to <18 years; and described the effects of > or = 1 of 3 pharmaceutical technologic aspects of an oral pediatric drug (formulation and dosage form; route and frequency of administration; and/or packaging, administration device, and user instruction) on > or = 1 of 6 patient-related outcomes (clinical efficacy, side effects and tolerability, patient preference, patient acceptance, administration errors, and/or adherence). Studies were excluded if they concerned a nonallopathic drug (ie, homeopathic remedy, anthroposophic drug, herbal supplement, or food supplement); related to asthma (because modern asthma treatment protocols strongly favor the use of drug inhalation above oral medication); and/or related to analgesics. The characteristics of each of the included publications were assessed with respect to pharmaceutical technologic aspect studied; patient-related outcomes studied; pharmacotherapeutic indication; year of publication; geographic location; number and age of the included subjects; and sponsorship by industry and/or author affiliation with the pharmaceutical industry. The electronic search was supplemented with a manual search of the cited references., Results: Ninety-four publications were identified as eligible for inclusion. These publications reported on 176 assessments of the effects of > or = 1 pharmaceutical technologic aspect on > or = 1 patient-related outcome. Fifty-five percent of the studies were conducted in children aged 2 or 3 years, and 69% in children aged 4 or 5 years. Forty-three percent of the publications included > or = 100 patients. Fifty-one percent of the studies were conducted in the United States or Canada, and 29% in Europe. Antibacterials for systemic use were the subject of 30% of the included publications. Two of the 94 publications were of appropriate methodologic quality (Jadad score > or = 4). Forty-nine percent of the studies were sponsored by the pharmaceutical industry or were written by > or = 1 author affiliated with the industry. Sixty-eight percent of the included studies had Jadad scores of 0 or 1 (poor quality). The proportion of industry-sponsored or industry-authored studies with a Jadad score > or = 2 or in > or = 100 children was not significantly different from that of non-industry-sponsored or-authored studies. The proportion of industry-sponsored or industry-authored studies conducted in the United States/Canada (48 [51%]) was not significantly different from that of studies conducted elsewhere (46 [49%]). The distribution of technologic aspects assessed in the included studies were formulation and dosage form, 48%; route and frequency of administration, 44%; and packaging, administration device, and user instruction, 8%. Seventy-six assessments included > or = 100 patients. Twenty-one of these assessments addressed patient acceptance or patient preference; 17, clinical efficacy; and 14, side effects and tolerability., Conclusions: This systematic review identified 94 articles on oral drugs for use in children and adolescents, which reported on a total 176 assessments of the effects of 3 pharmaceutical technologic aspects (formulation and dosage form; route and frequency of administration; and packaging, administration device, and user instruction) on 6 patient-related outcomes (clinical efficacy, side effects and tolerability, patient preference, patient acceptance, administration errors, and adherence). Only 2 of the 94 publications were of appropriate methodologic quality. These results suggest that published clinical evidence to support pharmaceutical development programs is limited., (Copyright 2010 Excerpta Medica Inc. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
35. Antenatal allopurinol for reduction of birth asphyxia induced brain damage (ALLO-Trial); a randomized double blind placebo controlled multicenter study.
- Author
-
Kaandorp JJ, Benders MJ, Rademaker CM, Torrance HL, Oudijk MA, de Haan TR, Bloemenkamp KW, Rijken M, van Pampus MG, Bos AF, Porath MM, Oetomo SB, Willekes C, Gavilanes AW, Wouters MG, van Elburg RM, Huisjes AJ, Bakker SC, van Meir CA, von Lindern J, Boon J, de Boer IP, Rijnders RJ, Jacobs CJ, Uiterwaal CS, Mol BW, Visser GH, van Bel F, and Derks JB
- Subjects
- Asphyxia Neonatorum blood, Asphyxia Neonatorum complications, Asphyxia Neonatorum epidemiology, Biomarkers blood, Double-Blind Method, Female, Fetal Hypoxia blood, Fetal Hypoxia complications, Humans, Hypoxia-Ischemia, Brain blood, Hypoxia-Ischemia, Brain etiology, Infant, Newborn, Multivariate Analysis, Nerve Growth Factors blood, Netherlands epidemiology, Phosphopyruvate Hydratase blood, Pilot Projects, Pregnancy, Prospective Studies, Regression Analysis, S100 Calcium Binding Protein beta Subunit, S100 Proteins blood, Xanthine Oxidase antagonists & inhibitors, Allopurinol therapeutic use, Asphyxia Neonatorum prevention & control, Fetal Hypoxia prevention & control, Free Radical Scavengers therapeutic use, Hypoxia-Ischemia, Brain prevention & control, Prenatal Care methods
- Abstract
Background: Hypoxic-ischaemic encephalopathy is associated with development of cerebral palsy and cognitive disability later in life and is therefore one of the fundamental problems in perinatal medicine. The xanthine-oxidase inhibitor allopurinol reduces the formation of free radicals, thereby limiting the amount of hypoxia-reperfusion damage. In case of suspected intra-uterine hypoxia, both animal and human studies suggest that maternal administration of allopurinol immediately prior to delivery reduces hypoxic-ischaemic encephalopathy., Methods/design: The proposed trial is a randomized double blind placebo controlled multicenter study in pregnant women at term in whom the foetus is suspected of intra-uterine hypoxia.Allopurinol 500 mg IV or placebo will be administered antenatally to the pregnant woman when foetal hypoxia is suspected. Foetal distress is being diagnosed by the clinician as an abnormal or non-reassuring foetal heart rate trace, preferably accompanied by either significant ST-wave abnormalities (as detected by the STAN-monitor) or an abnormal foetal blood scalp sampling (pH < 7.20).Primary outcome measures are the amount of S100B (a marker for brain tissue damage) and the severity of oxidative stress (measured by isoprostane, neuroprostane, non protein bound iron and hypoxanthine), both measured in umbilical cord blood. Secondary outcome measures are neonatal mortality, serious composite neonatal morbidity and long-term neurological outcome. Furthermore pharmacokinetics and pharmacodynamics will be investigated.We expect an inclusion of 220 patients (110 per group) to be feasible in an inclusion period of two years. Given a suspected mean value of S100B of 1.05 ug/L (SD 0.37 ug/L) in the placebo group this trial has a power of 90% (alpha 0.05) to detect a mean value of S100B of 0.89 ug/L (SD 0.37 ug/L) in the 'allopurinol-treated' group (z-test2-sided). Analysis will be by intention to treat and it allows for one interim analysis., Discussion: In this trial we aim to answer the question whether antenatal allopurinol administration reduces hypoxic-ischaemic encephalopathy in neonates exposed to foetal hypoxia., Trial Registration Number: Clinical Trials, protocol registration system: NCT00189007.
- Published
- 2010
- Full Text
- View/download PDF
36. Maternal allopurinol during fetal hypoxia lowers cord blood levels of the brain injury marker S-100B.
- Author
-
Torrance HL, Benders MJ, Derks JB, Rademaker CM, Bos AF, Van Den Berg P, Longini M, Buonocore G, Venegas M, Baquero H, Visser GH, and Van Bel F
- Subjects
- Adult, Allopurinol blood, Chromatography, High Pressure Liquid methods, Double-Blind Method, Feasibility Studies, Female, Fetal Hypoxia prevention & control, Fetus drug effects, Fetus physiology, Free Radical Scavengers blood, Humans, Pilot Projects, Pregnancy, S100 Calcium Binding Protein beta Subunit, Young Adult, Allopurinol administration & dosage, Fetal Blood metabolism, Fetal Hypoxia metabolism, Free Radical Scavengers administration & dosage, Maternal-Fetal Exchange physiology, Nerve Growth Factors blood, S100 Proteins blood
- Abstract
Background: Fetal hypoxia is an important determinant of neonatal encephalopathy caused by birth asphyxia, in which hypoxia-induced free radical formation plays an important role., Hypothesis: Maternal treatment with allopurinol, will cross the placenta during fetal hypoxia (primary outcome) and reduce S-100B and free radical formation (secondary outcome)., Methods: In a randomized, double-blind feasibility study, 53 pregnant women in labor (54 fetuses) with a gestational age of >36 weeks and fetal hypoxia, as indicated by abnormal/nonreassuring fetal heart rate tracing or fetal scalp pH of <7.20, received 500 mg of allopurinol or placebo intravenously. Severity of fetal hypoxia, brain damage and free radical formation were assessed by arterial cord blood lactate, S-100B and non-protein-bound-iron concentrations, respectively. At birth, maternal and cord blood concentrations of allopurinol and its active metabolite oxypurinol were determined., Results: Allopurinol and oxypurinol concentrations were within the therapeutic range in the mother (allopurinol > 2 mg/L and/or oxypurinol > 4 mg/L) but not always in arterial cord blood. We therefore created 3 groups: a placebo (n = 27), therapeutic allopurinol (n = 15), and subtherapeutic allopurinol group (n = 12). Cord lactate concentration did not differ, but S-100B was significantly lower in the therapeutic allopurinol group compared with the placebo and subtherapeutic allopurinol groups (P < .01). Fewer therapeutic allopurinol cord samples had measurable non-protein-bound iron concentrations compared with placebo (P < .01)., Conclusions: Maternal allopurinol/oxypurinol crosses the placenta during fetal hypoxia. In fetuses/newborns with therapeutic allopurinol/oxypurinol concentrations in cord blood, lower plasma levels of the brain injury marker protein S-100B were detected. A larger allopurinol trial in compromised fetuses at term seems warranted. The allopurinol dosage must be adjusted to achieve therapeutic fetal allopurinol/oxypurinol concentrations.
- Published
- 2009
- Full Text
- View/download PDF
37. The effect of computerized physician order entry on medication prescription errors and clinical outcome in pediatric and intensive care: a systematic review.
- Author
-
van Rosse F, Maat B, Rademaker CM, van Vught AJ, Egberts AC, and Bollen CW
- Subjects
- Adult, Child, Humans, Infant, Newborn, Intensive Care Units, Neonatal organization & administration, Intensive Care Units, Pediatric organization & administration, Medication Errors statistics & numerical data, Intensive Care Units organization & administration, Medical Order Entry Systems, Medication Errors prevention & control
- Abstract
Context: Pediatric and intensive care patients are particularly at risk for medication errors. Computerized physician order entry systems could be effective in reducing medication errors and improving outcome. Effectiveness of computerized physician order entry systems has been shown in adult medical care. However, in critically ill patients and/or children, medication prescribing is a more complex process, and usefulness of computerized physician order entry systems has yet to be established., Objective: To evaluate the effects of computerized physician order entry systems on medication prescription errors, adverse drug events, and mortality in inpatient pediatric care and neonatal, pediatric or adult intensive care settings., Methods: PubMed, the Cochrane library, and Embase up to November 2007 were used as our data sources. Inclusion criteria were studies of (1) children 0 to 18 years old and/or ICU patients (including adults), (2) computerized physician order entry versus no computerized physician order entry as intervention, and (3) randomized trial or observational study design. All studies were validated, and data were analyzed. RESULTS. Twelve studies, all observational, met our inclusion criteria. Eight studies took place at an ICU: 4 were adult ICUs, and 4 were PICUs and/or NICUs. Four studies were pediatric inpatient studies. Meta-analysis showed a significant decreased risk of medication prescription errors with use of computerized physician order entry. However, there was no significant reduction in adverse drug events or mortality rates. A qualitative assessment of studies revealed the implementation process of computerized physician order entry software as a critical factor for outcome., Conclusions: Introduction of computerized physician order entry systems clearly reduces medication prescription errors; however, clinical benefit of computerized physician order entry systems in pediatric or ICU settings has not yet been demonstrated. The quality of the implementation process could be a decisive factor determining overall success or failure.
- Published
- 2009
- Full Text
- View/download PDF
38. Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation.
- Author
-
Bartelink IH, Bredius RG, Ververs TT, Raphael MF, van Kesteren C, Bierings M, Rademaker CM, den Hartigh J, Uiterwaal CS, Zwaveling J, and Boelens JJ
- Subjects
- Administration, Oral, Adolescent, Age Factors, Busulfan adverse effects, Busulfan pharmacokinetics, Child, Child, Preschool, Disease-Free Survival, Dose-Response Relationship, Drug, Female, Humans, Infant, Infusions, Intravenous, Male, Myeloablative Agonists adverse effects, Myeloablative Agonists pharmacokinetics, Transplantation, Homologous, Busulfan administration & dosage, Drug Monitoring, Hematopoietic Stem Cell Transplantation methods, Myeloablative Agonists administration & dosage, Transplantation Conditioning methods
- Abstract
Because of intra- and interindividual variability, bioavailability, and pharmacokinetics of busulfan (Bu) in children, oral busulfan without therapeutic drug monitoring (TDM) is assumed to be associated with higher graft failure rates as well as higher toxicity (eg, veno-occlusive disease [VOD]). This study compares the outcome of hematopoietic stem cell transplantation (HSCT) of 2 groups: 1) 30 patients who received myeloablation with once-daily intravenous (i.v.) dose-targeted busulfan (BUdtIV) based on TDM and 2) 30 patients who received the current practice of untargeted oral busulfan (BUPO). Patients received a 3-hour infusion of Bu at a first dose of 120 mg/m(2) (age >or=1 year) or 80 mg/m(2) (<1 year), or BUPO 1 mg/kg 4 times daily. Both regimens were continued for 4 days. The target area under the curve (AUC) was defined as 17,500 microg *h/l. BUdtIV resulted in higher event-free survival (EFS) and survival rates compared to BUPO (EFS: 30% versus 83%, P < .001, survival: 53% versus 83%, P = .016). BUdtIV was associated with more cases of VOD. TDM was feasible in routine clinical practice. The results show that i.v. Bu using TDM is preferable over oral Bu in children undergoing allogeneic stem cell transplantation, especially in those at high risk for graft failure/relapse.
- Published
- 2008
- Full Text
- View/download PDF
39. Psychological side effects of MTX treatment in juvenile idiopathic arthritis: a pilot study.
- Author
-
van der Meer A, Wulffraat NM, Prakken BJ, Gijsbers B, Rademaker CM, and Sinnema G
- Subjects
- Adaptation, Psychological, Adolescent, Antirheumatic Agents therapeutic use, Anxiety chemically induced, Anxiety psychology, Anxiety therapy, Child, Child, Preschool, Female, Humans, Male, Methotrexate therapeutic use, Nausea chemically induced, Nausea therapy, Pilot Projects, Retrospective Studies, Stress, Psychological, Antirheumatic Agents adverse effects, Arthritis, Juvenile drug therapy, Methotrexate adverse effects, Nausea psychology, Psychotherapy
- Abstract
Objective: To document the psychological side effects of methotrexate (MTX) treatment in children with juvenile idiopathic arthritis (JIA) and to explore the usefulness of psychological therapy to ameliorate these side effects., Methods: The patients included in this study consisted of 29 patients with JIA using MTX. Of these, ten were referred to a pediatric psychologist because of MTX side effects, and had behavioural therapy to cope with these side effects with a strong behavioural component (anticipatory nausea, anxiety). The behavioural therapy was adapted to age and used systemic desensitization (distraction in a positive atmosphere) or cognitive behavioural therapy (relaxation and overruling negative thoughts by positive ones). The parents of the 29 children were interviewed about MTX treatment and the side effects their child had developed. Parents of children referred to the psychologist were also interviewed for their impression of the results of the behavioural therapy., Results: Prior to the behavioural therapy, nine out of 10 children reported MTX related nausea. Six of these ten were nauseous even before the administration and developed anticipatory nausea. Nine out of ten patients also showed some sign of distress in anticipation of MTX treatment, either orally of via injections. The behavioural therapy they had fully abolished side effects in five children and decreased the severity of nausea and distress in two children. Of the remaining nineteen children, not referred to the pediatric psychologist, 11 reported nausea after MTX treatment and four of these developed anticipatory nausea. In addition, eight of these 18 developed behavioural distress in anticipation of the treatment., Conclusion: This study showed that children with JIA who receive MTX treatment frequently develop psychological side effects, such as anticipatory nausea and behavioural distress in anticipation of treatment. This is true for patients selected for reported MTX side effects, as well as for randomly chosen JIA patients using MTX. As MTX is still the first choice in the treatment of severe JIA, more attention should be given to the treatment and prevention of side effects. Psychological intervention can be of help, but further studies are needed on the nature of the side effects, as well as on the prerequisites and efficacy of behavioural therapy.
- Published
- 2007
40. Development of an optimal lidocaine infusion strategy for neonatal seizures.
- Author
-
Malingré MM, Van Rooij LG, Rademaker CM, Toet MC, Ververs TF, van Kesteren C, and de Vries LS
- Subjects
- Anti-Arrhythmia Agents adverse effects, Anti-Arrhythmia Agents blood, Anti-Arrhythmia Agents pharmacokinetics, Anticonvulsants administration & dosage, Anticonvulsants adverse effects, Arrhythmias, Cardiac chemically induced, Arrhythmias, Cardiac epidemiology, Dose-Response Relationship, Drug, Follow-Up Studies, Gestational Age, Humans, Infant, Infant, Newborn, Infusions, Intravenous, Intensive Care Units, Neonatal, Lidocaine adverse effects, Lidocaine blood, Lidocaine pharmacokinetics, Netherlands, Recurrence, Risk Factors, Time Factors, Treatment Outcome, Anti-Arrhythmia Agents administration & dosage, Lidocaine administration & dosage, Seizures drug therapy
- Abstract
Introduction: Lidocaine is an effective drug for the treatment of neonatal convulsions not responding to traditional anticonvulsant therapy. However, one of the side-effects is a risk of cardiac arrhythmias. The aim of this study was to develop an optimal dosing strategy with minimal risk of cardiac arrhythmias., Materials and Methods: As a first step, we studied 20 neonates during routine treatment of neonatal seizures with lidocaine. All were given a loading dose of 2 mg/kg in 10 min, followed by the continuous infusion of 6 mg/kg per hour for 12 h, 4 mg/kg per hour for 12 h and finally 2 mg/kg per hour for 12 h. Effectiveness, cardiac toxicity and lidocaine plasma concentrations were then determined., Results: No cardiac arrhythmias were observed, and lidocaine was effective in 76% of the treatments. In most of the treatments (13 out of 20) maximal lidocaine plasma concentrations were >9 mg/L. Plasma levels >9 mg/L have been related to cardiac toxicity when used as an anti-arrhythmic drug in adults. It was of interest that all preterm infants showed high lidocaine plasma levels. Secondly, we developed the optimal dosing regimen, which was defined as an infusion regimen at which maximal lidocaine plasma concentrations are <9 mg/L. Simulations with the developed pharmacokinetic model indicated a reduction in the infusion duration of lidocaine at 6 mg/kg per hour from 12 to 6 h. Thirdly, the new lidocaine dosing regimen was evaluated. Fifteen neonates (16 treatments) were studied. No cardiac arrhythmias were observed, and lidocaine was effective in 78% of the treatments. In most of the treatments (11 out of 16) maximal lidocaine plasma concentrations were <9 mg/L. Again preterm infants showed relatively high lidocaine plasma levels., Conclusion: A new lidocaine dosing schedule was developed. This new regimen should have a lower risk of cardiac arrhythmias and appears to be as effective in term infants. For preterm infants the optimal regimen needs to be determined.
- Published
- 2006
- Full Text
- View/download PDF
41. Population pharmacokinetics of allopurinol in full-term neonates with perinatal asphyxia.
- Author
-
van Kesteren C, Benders MJ, Groenendaal F, van Bel F, Ververs FF, and Rademaker CM
- Subjects
- Allopurinol blood, Clinical Trials as Topic, Double-Blind Method, Free Radical Scavengers blood, Humans, Infant, Newborn, Metabolic Clearance Rate, Models, Biological, Allopurinol pharmacokinetics, Asphyxia Neonatorum drug therapy, Free Radical Scavengers pharmacokinetics
- Abstract
In newborn infants, allopurinol is being tested as a free radical scavenger to prevent brain damage caused by reperfusion and oxygenation after perinatal hypoxia and ischemia (birth asphyxia). To develop rational dosing schemes for future studies, knowledge of the pharmacokinetics in this patient group is essential. In the present study, a population pharmacokinetic model was designed and validated for allopurinol in this specific patient group. One-compartment and 2-compartment models were fitted to plasma concentration time data of 24 newborns entered in 2 clinical trials using nonlinear mixed effects modeling. A bootstrap procedure was performed to check the robustness of the model. The data were best described using a 1-compartment model with linear elimination. Estimated pharmacokinetic parameters were volume of the central compartment (V, 0.79 L/kg) and total body clearance (CL, 0.078 L/h/kg), with 42% and 60% interindividual variability, respectively. The median values for these parameters of 1000 bootstrap replicates were very similar (95% confidence intervals were 0.67 to 0.96 and 0.054 to 0.10 for V and CL, respectively), indicating the robustness of the model. A population pharmacokinetic model has been designed and validated which adequately describes the data of 2 clinical studies in critically ill newborn infants. The model will be used to design dosing strategies for future evaluation of the benefits of allopurinol in these patients.
- Published
- 2006
- Full Text
- View/download PDF
42. Early postnatal allopurinol does not improve short term outcome after severe birth asphyxia.
- Author
-
Benders MJ, Bos AF, Rademaker CM, Rijken M, Torrance HL, Groenendaal F, and van Bel F
- Subjects
- Brain Ischemia etiology, Double-Blind Method, Free Radicals adverse effects, Humans, Infant, Newborn, Reperfusion Injury etiology, Treatment Outcome, Allopurinol therapeutic use, Asphyxia Neonatorum drug therapy, Brain Ischemia prevention & control, Free Radical Scavengers therapeutic use, Reperfusion Injury prevention & control
- Abstract
Objective: To investigate whether postnatal allopurinol would reduce free radical induced reperfusion/reoxygenation injury of the brain in severely asphyxiated neonates., Method: In an interim analysis of a randomised, double blind, placebo controlled study, 32 severely asphyxiated infants were given allopurinol or a vehicle within four hours of birth., Results: The analysis showed an unaltered (high) mortality and morbidity in the infants treated with allopurinol., Conclusion: Allopurinol treatment started postnatally was too late to reduce the early reperfusion induced free radical surge. Allopurinol administration to the fetus with (imminent) hypoxia via the mother during labour may be more effective in reducing free radical induced post-asphyxial brain damage.
- Published
- 2006
- Full Text
- View/download PDF
43. Health Care Failure Mode and Effect Analysis: a useful proactive risk analysis in a pediatric oncology ward.
- Author
-
van Tilburg CM, Leistikow IP, Rademaker CM, Bierings MB, and van Dijk AT
- Subjects
- Adolescent, Adult, Antineoplastic Agents, Phytogenic administration & dosage, Antineoplastic Agents, Phytogenic therapeutic use, Child, Child, Preschool, Drug Prescriptions, Hospitals, Pediatric, Hospitals, University, Humans, Infant, Infant, Newborn, Medical Oncology, Netherlands, Patient Care Team, Risk Assessment, Vincristine administration & dosage, Vincristine therapeutic use, Medical Errors prevention & control, Quality Assurance, Health Care, Safety Management
- Abstract
Background: Pediatric inpatient settings are known for their high medication error rate. The aim of this study was to investigate whether the Health Care Failure Mode and Effect Analysis (HFMEA) is a valid proactive method to evaluate circumscribed health care processes like prescription up to and including administration of chemotherapy (vincristine) in the pediatric oncology inpatient setting., Methods: A multidisciplinary team consisting of a team leader, pharmacy, nursing and medical staff and a patient's parent was assembled in a pediatric oncology ward with a computerized physician order entry system. A flow diagram of the process was made and potential failure modes were identified and evaluated using a hazard scoring matrix. Using a decision tree, it was determined for which failure mode recommendations had to be made., Results: The process was divided into three main parts: prescription, processing by the pharmacy, and administration. Fourteen out of 61 failure modes were classified as high risk, 10 of which were sufficiently covered by current protocols. For the other four failure modes, five recommendations were made. Four additional recommendations were made concerning non-high risk failure modes. Most of them were implemented by the hospital management. The whole process took seven meetings and a total of 140 man-hours., Conclusions: The systematic approach of HFMEA by a multidisciplinary team is a useful method for detecting failure modes. A patient or a parent of a patient contributes to the multidisciplinarity of the team.
- Published
- 2006
- Full Text
- View/download PDF
44. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations.
- Author
-
Bartelink IH, Rademaker CM, Schobben AF, and van den Anker JN
- Subjects
- Age Factors, Body Surface Area, Body Weight, Child, Child, Preschool, Humans, Infant, Infant, Newborn, Intestinal Absorption, Intestinal Mucosa metabolism, Kidney metabolism, Liver metabolism, Models, Biological, Pharmaceutical Preparations blood, Pharmaceutical Preparations urine, Practice Guidelines as Topic, Tissue Distribution, Aging metabolism, Pharmaceutical Preparations administration & dosage, Pharmaceutical Preparations metabolism, Pharmacokinetics
- Abstract
The approach to paediatric drug dosing needs to be based on the physiological characteristics of the child and the pharmacokinetic parameters of the drug. This review summarises the current knowledge on developmental changes in absorption, distribution, metabolism and excretion and combines this knowledge with in vivo and in vitro pharmacokinetic data that are currently available. In addition, dosage adjustments based on practical problems, such as child-friendly formulations and feeding regimens, disease state, genetic make-up and environmental influences are presented. Modification of a dosage based on absorption, depends on the route of absorption, the physico chemical properties of the drug and the age of the child. For oral drug absorption, a distinction should be made between the very young and children over a few weeks old. In the latter case, it is likely that practical considerations, like appropriate formulations, have much greater relevance to oral drug absorption. The volume of distribution (V(d)) may be altered in children. Hydrophilic drugs with a high V(d) in adults should be normalised to bodyweight in young children (age <2 years), whereas hydrophilic drugs with a low V(d) in adults should be normalised to body surface area (BSA) in these children. For drugs that are metabolised by the liver, the effect of the V(d) becomes apparent in children <2 months of age. In general, only the first dose should be based on the V(d); subsequent doses should be determined by the clearance. Pharmacokinetic studies on renal and liver function clarify that a distinction should be made between maturation and growth of the organs. After the maturation process has finished, the main influences on the clearance of drugs are growth and changes in blood flow of the liver and kidney. Drugs that are primarily metabolised by the liver should be administered with extreme care until the age of 2 months. Modification of dosing should be based on response and on therapeutic drug monitoring. At the age of 2-6 months, a general guideline based on bodyweight may be used. After 6 months of age, BSA is a good marker as a basis for drug dosing. However, even at this age, drugs that are primarily metabolised by cytochrome P450 2D6 and uridine diphosphate glucuronosyltransferase should be normalised to bodyweight. In the first 2 years of life, the renal excretion rate should be determined by markers of renal function, such as serum creatinine and p-aminohippuric acid clearance. A dosage guideline for drugs that are significantly excreted by the kidney should be based on the determination of renal function in first 2 years of life. After maturation, the dose should be normalised to BSA. These guidelines are intended to be used in clinical practice and to form a basis for more research. The integration of these guidelines, and combining them with pharmacodynamic effects, should be considered and could form a basis for further study.
- Published
- 2006
- Full Text
- View/download PDF
45. Treatment of symptomatic congenital cytomegalovirus infection with valganciclovir.
- Author
-
Meine Jansen CF, Toet MC, Rademaker CM, Ververs TF, Gerards LJ, and van Loon AM
- Subjects
- Cytomegalovirus Infections virology, Evoked Potentials, Auditory, Brain Stem physiology, Ganciclovir administration & dosage, Hearing Loss, Sensorineural prevention & control, Humans, Infant, Newborn, Male, Valganciclovir, Viral Load, Antiviral Agents administration & dosage, Cytomegalovirus, Cytomegalovirus Infections congenital, Cytomegalovirus Infections drug therapy, Ganciclovir analogs & derivatives
- Abstract
Cytomegalovirus (CMV) is the most common cause of congenital infection in humans. Some congenitally infected infants will develop sequelae later in life, especially sensorineural hearing loss (SNHL) and mental retardation. There is no generally accepted antiviral therapy for the treatment of symptomatic congenital CMV infections yet. We present a neonate with symptomatic congenital CMV infection, who was treated with intravenous (iv) ganciclovir (GCV) during 18 days and subsequently with oral valganciclovir (VGCV) for 5.5 months, in an attempt to prevent development of SNHL. GCV was given intravenously 10 mg/kg/day in two doses and VGCV doses ranged from 280-850 mg/m2 bidaily (bid). Our experience shows that it is not possible to give a fixed dosing regime for VGCV in neonates and that continuous adaptation of dose is necessary to achieve stable target levels of GCV and to keep the viral load in urine at undetectable level. At 18 months of age no hearing deterioration has occurred. While the current findings are encouraging, the limitations of a single case report with a relatively short follow-up emphasizes the need for further prospective randomized studies to evaluate pharmacokinetics, efficacy and safety of VGCV therapy in neonates with congenital CMV infection.
- Published
- 2005
- Full Text
- View/download PDF
46. Midazolam and amplitude-integrated EEG in asphyxiated full-term neonates.
- Author
-
van Leuven K, Groenendaal F, Toet MC, Schobben AF, Bos SA, de Vries LS, and Rademaker CM
- Subjects
- Anticonvulsants therapeutic use, Asphyxia Neonatorum blood, Asphyxia Neonatorum complications, Brain drug effects, Brain physiopathology, Gestational Age, Humans, Infant, Newborn, Midazolam therapeutic use, Prospective Studies, Seizures blood, Seizures drug therapy, Seizures etiology, Anticonvulsants blood, Anticonvulsants pharmacology, Asphyxia Neonatorum physiopathology, Electroencephalography drug effects, Midazolam blood, Midazolam pharmacology
- Abstract
Aim: In the present, prospective study, the relation between the levels of midazolam, its two active metabolites--1-hydroxy-midazolam (OH-midazolam) and 1-hydroxy-midazolam-glucuronide (glu-midazolam)--and the aEEG were examined., Patients and Methods: Fifteen full-term neonates with seizures due to hypoxic-ischaemic encephalopathy admitted to our NICU were included. Midazolam (loading dose 0.05 mg/kg in 10 min, maintenance dose 0.15 mg/kg/h) was used as an add-on anti-convulsant after phenobarbital and lidocaine because of continuing seizures. Amplitude-integrated EEG background pattern was scored at the start of midazolam and at the time of blood sampling as continuous normal voltage (CNV), discontinuous normal voltage (DNV), burst suppression (BS), continuous low voltage (CLV) or flat trace (FT). Serum levels of midazolam, OH-midazolam and glu-midazolam were measured at least 8 h after the start with HPLC., Results: In 11/15 patients, seizures were abolished with the addition of midazolam. In the remaining patients, seizure frequency was reduced in one and unchanged in three. Amplitude-integrated EEG background pattern at the start of midazolam was CNV in two, DNV in six, BS in five and CLV in two. Moderate, temporary suppression of the aEEG background pattern lasting less than 2 h was seen in four neonates. Amplitude-integrated EEG at midazolam sampling was CNV in two, DNV in seven, CLV in two and FT in four. Serum levels of midazolam ranged from 0.10 to 1.76 mg/l, OH-midazolam from 0.05 to 0.28 mg/l and glu-midazolam from 0.85 to 4.36 mg/l., Conclusions: A brief and moderate suppression of the aEEG background pattern immediately after midazolam was seen in four neonates for less than 2 h. Suppression at a later time point, i.e. after more than 8 h of midazolam infusion, was demonstrated almost exclusively in neonates with a poor background pattern, and therefore these patterns appear to be determined mainly by the severity of hypoxic-ischaemic encephalopathy.
- Published
- 2004
47. Safety of anti-TNFalpha therapy in children with juvenile idiopathic arthritis.
- Author
-
Dekker L, Armbrust W, Rademaker CM, Prakken B, Kuis W, and Wulffraat NM
- Subjects
- Adolescent, Child, Child, Preschool, Etanercept, Humans, Infliximab, Receptors, Tumor Necrosis Factor, Antibodies, Monoclonal adverse effects, Antirheumatic Agents adverse effects, Arthritis, Juvenile drug therapy, Immunoglobulin G adverse effects, Recombinant Fusion Proteins, Tumor Necrosis Factor-alpha
- Abstract
Anti-TNFalpha agents are frequently used in the treatment of severe JIA. Etanercept, a fully human soluble recombinant tumour necrosis factor p75 receptor Fc fusion protein, has been registered for the treatment of polyarticular course JIA patients who fail to respond to or do not tolerate methotrexate (MTX). Infliximab, a chimeric human-mouse monoclonal antibody to TNFalpha, is expected to be registered soon for JIA and Crohn's disease (CD) in children. As in adults, both agents are effective in controlling inflammation and inhibiting the progression of joint destruction. Despite this good clinical efficacy, the physician must remain alert for potential side effects, especially after prolonged use. This review gives an overview of the reported adverse events.
- Published
- 2004
48. Pharmacokinetics and effects of propofol 6% for short-term sedation in paediatric patients following cardiac surgery.
- Author
-
Knibbe CA, Melenhorst-de Jong G, Mestrom M, Rademaker CM, Reijnvaan AF, Zuideveld KP, Kuks PF, van Vught H, and Danhof M
- Subjects
- Adult, Child, Preschool, Chromatography, High Pressure Liquid methods, Dose-Response Relationship, Drug, Humans, Hypnotics and Sedatives administration & dosage, Infant, Infusions, Intravenous, Propofol administration & dosage, Hypnotics and Sedatives pharmacokinetics, Propofol pharmacokinetics, Thoracic Surgical Procedures
- Abstract
Aims: This paper describes the pharmacokinetics and effects of propofol in short-term sedated paediatric patients., Methods: Six mechanically ventilated children aged 1-5 years received a 6 h continuous infusion of propofol 6% at the rate of 2 or 3 mg kg-1 h-1 for sedation following cardiac surgery. A total of seven arterial blood samples was collected at various time points during and after the infusion in each patient. Pharmacokinetic modelling was performed using NONMEM. Effects were assessed on the basis of the Ramsay sedation score as well as a subjective sedation scale., Results: The data were best described by a two-compartment pharmacokinetic model. In the model, body weight was a significant covariate for clearance. Pharmacokinetic parameters in the weight-proportional model were clearance (CL) = 35 ml kg-1 min-1, volume of central compartment (V1) = 12 l, intercompartmental clearance (Q) = 0.35 l min-1 and volume of peripheral compartment (V2) = 24 l. The interindividual variabilities for these parameters were 8%, < 1%, 11% and 35%, respectively. Compared with the population pharmacokinetics in adults following cardiac surgery and when normalized for body weight, statistically significant differences were observed the parameters CL and V1 (35 vs 29 ml kg-1 min-1 and 0.78 vs 0.26 l kg-1P < 0.05), whereas the values for Q and V2 were similar (23 vs 18 ml kg-1 min-1 and 1.6 vs 1.8 l kg-1, P > 0.05). In children, the percentage of adequately sedated patients was similar compared with adults (50% vs 67%) despite considerably higher propofol concentrations (1.3 +/- 0.10 vs 0.51 +/- 0.035 mg l-1, mean +/- s.e. mean), suggesting a lower pharmacodynamic sensitivity to propofol in children., Conclusions: In children aged 1-5 years, a pharmacokinetic model for propofol was described using sparse data. In contrast to adults, body weight was a significant covariate for clearance in children. The model may serve as a useful basis to study the role of covariates in the pharmacokinetics and pharmacodynamics of propofol in paediatric patients of different ages.
- Published
- 2002
- Full Text
- View/download PDF
49. Effects of magnesium sulphate on amplitude-integrated continuous EEG in asphyxiated term neonates.
- Author
-
Groenendaal F, Rademaker CM, Toet MC, and de Vries LS
- Subjects
- Asphyxia Neonatorum physiopathology, Double-Blind Method, Humans, Infant, Newborn, Pilot Projects, Electroencephalography drug effects, Hypoxia-Ischemia, Brain physiopathology, Magnesium Sulfate pharmacology
- Abstract
Unlabelled: In this study it is hypothesized that magnesium sulphate in asphyxiated full-term neonates could lead to a gradual improvement in background pattern of the amplitude integrated EEG (aEEG), an early marker of hypoxic-ischaemic brain injury. In a double-blind, randomized, controlled pilot study of 22 asphyxiated full-term neonates 8 received magnesium sulphate, reaching serum Mg2+ levels of 2.5 mmol/L. Magnesium sulphate had no immediate effect on aEEG-patterns. At 12 h of age, aEEG was more depressed compared with aEEG at 3 h in 6 of the 8 magnesium-treated neonates, and in 3 of the 14 placebo-treated neonates (Mg2+ vs placebo: p < 0.05, Mann-Whitney). No further significant changes in aEEG were seen between 12 and 24 h. Outcome was unfavourable in 4 of the 8 magnesium-treated neonates, and in 8 of the 14 placebo-treated neonates., Conclusion: Magnesium sulphate did not have a positive effect on aEEG patterns in this small group of asphyxiated term neonates.
- Published
- 2002
- Full Text
- View/download PDF
50. Once-daily versus multiple-daily gentamicin in infants and children.
- Author
-
Uijtendaal EV, Rademaker CM, Schobben AF, Fleer A, Kramer WL, van Vught AJ, Kimpen JL, and van Dijk A
- Subjects
- Adolescent, Anti-Bacterial Agents adverse effects, Anti-Bacterial Agents pharmacokinetics, C-Reactive Protein, Child, Child, Preschool, Creatinine blood, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Monitoring, Drug Therapy, Combination, Female, Gentamicins adverse effects, Gentamicins pharmacokinetics, Humans, Infant, Infusions, Intravenous, Kidney drug effects, Lactams, Male, Prospective Studies, Treatment Outcome, Anti-Bacterial Agents administration & dosage, Bacterial Infections drug therapy, Gentamicins administration & dosage
- Abstract
In this prospective randomized trial, the efficacy and safety of once-daily administration of gentamicin were compared with multiple-daily administration in infants and children. In addition, pharmacokinetic variables were calculated. Gentamicin therapy was started at a dose of 5 mg/kg per day under individual dose or dosage interval adjustments to achieve target levels. Fifty-two infants and children aged 1 month (postterm) to 16 years were enrolled. The duration of fever from the start of therapy, the percentage decline of C-reactive protein (CRP) on day 3 of treatment, and the clinical outcome were used as efficacy parameters. Nephrotoxicity was evaluated using creatinine serum levels. Basic characteristics in both groups were comparable. A good clinical response was observed in both groups. Fever may have resolved faster with multiple-daily administration, but this was not statistically significant. The percentage of decline of CRP was also comparable in both groups. Nephrotoxicity occurred in six patients, three per group. Many patients were too ill or too young to perform hearing tests, but no clinical signs of ototoxicity were observed. Mean doses of 6.8 mg/kg per day (multiple-daily administration) and 7.3 mg/kg per day (once-daily administration) were necessary to meet the target gentamicin levels. Triple-daily doses had to be reduced to a twice-daily regimen in 17 of 26 children. Dose and dosage interval adaptations can be performed by Bayesian forecasting using a one-compartment model with one set of K(e) and V(d) parameters. The authors consider both regimens equally effective, with a comparable incidence of nephrotoxicity. A starting dose of 6.5 mg/kg once daily is advised.
- Published
- 2001
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.